BRAF and cancer: Additionally, the subset of the BRAF mutated melanoma cohort of the cancer genome atlas (TCGA) harboring an EZH2 silent mutation, showed a highly significant enforced miR-129-5p expression compared to BRAF mutated melanoma patients with EZH2 wildtype (Figure 3E).